triazoles has been researched along with azd2014 in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Andreeff, M; Arai, H; Ciurea, S; Han, L; Kaga, N; Kazuno, S; Kikkawa, M; Konopleva, M; Miida, T; Saitoh, K; Sekihara, K; Tabe, Y; Taka, H; Yamamoto, S | 1 |
| Abadie-Lacourtoisie, S; Bazan, F; Chabaud, S; Colombe-Vermorel, A; Coquan, E; Dalban, C; Diaz, JJ; Fabbro, M; Frenel, JS; Garin, G; Heudel, PE; Marcel, V; Martinez, S; Mourksi, NE; Odeyer, L; Pérol, D; Ray-Coquard, I; Simioni, V; Tabone-Eglinger, S; Treilleux, I | 1 |
3 other study(ies) available for triazoles and azd2014
| Article | Year |
|---|---|
Targeting mantle cell lymphoma metabolism and survival through simultaneous blockade of mTOR and nuclear transporter exportin-1.
Topics: Acrylates; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Energy Metabolism; Exportin 1 Protein; Humans; Karyopherins; Lymphoma, Mantle-Cell; Morpholines; Proteome; Proteomics; Pyrimidines; Receptors, Cytoplasmic and Nuclear; Signal Transduction; TOR Serine-Threonine Kinases; Triazoles | 2017 |
Combination Vistusertib and Anastrozole Shows Benefit in Endometrial Cancer.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Benzamides; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Morpholines; Nitriles; Pyrimidines; Triazoles | 2022 |
Ribosome biogenesis-based predictive biomarkers in endocrine therapy (Anastrozole) combined with mTOR inhibitor (Vistusertib) in endometrial cancer: translational study from the VICTORIA trial in collaboration with the GINECO group.
Topics: Anastrozole; Antineoplastic Agents, Hormonal; Aromatase Inhibitors; Biomarkers; Breast Neoplasms; Endometrial Neoplasms; Female; Humans; Nitriles; Ribosomes; TOR Serine-Threonine Kinases; Triazoles | 2023 |